Immunome And Morphimmune Announce Definitive Merger Agreement And Simultaneous Private Placement Investment Of $125M To Develop Targeted Cancer Therapies
Portfolio Pulse from Benzinga Newsdesk
Immunome and Morphimmune have announced a definitive merger agreement, with a simultaneous private placement investment of $125M to develop targeted cancer therapies. The merged company will operate as Immunome and is expected to submit three investigational new drug applications within 18 months of closing. Clay B. Siegall, current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., will serve as Chairman and CEO of the combined company.
June 29, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunome is merging with Morphimmune and receiving a $125M investment to develop targeted cancer therapies. The merged company, operating as Immunome, is expected to submit three new drug applications within 18 months.
The merger with Morphimmune and the $125M investment are significant for Immunome as they will enable the development of targeted cancer therapies. The expectation of submitting three new drug applications within 18 months indicates a positive outlook for the company's pipeline, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100